Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
Key facts
- Where
- Amsterdam, Enschede, Groningen és Utrecht, HollandiaSee the 4 sites
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
- Medisch Spectrum TwenteEnschede, HollandiaTaking people
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
- Universitair Medisch Centrum UtrechtUtrecht, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2025-524129-42-00
- Record updated
- 2026. július 30.
- Original description
[PK] Determination of MTX-PG concentrations and identification of accumulation patterns over time in RBCs. [PD] Association of MTX-PG concentration with MTX discontinuation due to a lack of efficacy or toxicity.Read full original descriptionShow less
[PK] Determination of MTX-PG concentrations and identification of accumulation patterns over time in RBCs. [PD] Association of MTX-PG concentration with MTX discontinuation due to a lack of efficacy or toxicity.
Inclusion: Age of 4-28 years; Written informed consent of patient (if indicated) and parents (if indicated) has been obtained; Proven diagnosis of Crohn’s disease based on endoscopic, radiological and histologic findings; Will start MTX treatment monotherapy or combination therapy with infliximab.
Exclusion: Co-treatment with a biologic agent other than infliximab; Not eligible to receive MTX, as in usual care; Inability to read and understand the patient and family information sheets; Informed consent of patient has not been obtained when required.